Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Urol. 2020 Jan 23;204(1):63–70. doi: 10.1097/JU.0000000000000761

Table 2B.

Observed ORR by tumor histology subtype, per treatment line or primary tumor site

ORR (%) PUC VUC OR (95% CI) vs. PUC p value
First line (n= 199; 134 PUC, 65 VUC) 33% 28% 0.78 (0.41 - 1.50) 0.46
Subsequent (n = 196; 144 PUC, 52 VUC) 24% 31% 1.38 (0.69 - 2.79) 0.36
Upper tract (n= 51; 35 PUC, 16 VUC) 29% 13% 0.36 (0.07 – 1.87) 0.22
Lower tract (n= 325; 229 PUC, 96 VUC) 29% 33% 1.21 (0.73 – 2.02) 0.47

PUC, pure urothelial carcinoma; VUC, variant urothelial carcinoma